IP Explained: Understanding biopharmaceutical innovation
By Andrew Powaleny | July 30, 2019
Over the past 25 years, prescription medicines have transformed the trajectory of many debilitating diseases and conditions, including heart disease, HIV/AIDS, cancer and hepatitis C, resulting in...
Read More
IP Explained: Why IP protections are important for biologic medicines
By Tom Wilbur | July 18, 2019
Biologics are cutting-edge therapies that treat or cure some of the most challenging and costly diseases. These medicines are created from living organisms through highly complex manufacturing...
Read More
PhRMA member companies invested nearly $80 billion in R&D last year
By Tim McClung | July 18, 2019
Last year, PhRMA member companies invested a record-setting $79.6 billion in research and development (R&D) according to the 2019 PhRMA member annual survey.
Read More
Setting the record straight on international reference pricing
By Kevin Haninger | July 16, 2019
There’s been a lot of talk in Washington about how to help patients better access and afford their medicines. These are important discussions that will hopefully result in real affordability...
Read More
Four states adopt first-in-the-nation laws to protect patients from surprise insurer practices
By Nick McGee | July 15, 2019
West Virginia, Virginia, Arizona and Illinois recently became the first states in America to adopt patient-centered legislation to bring relief and more predictability to patients facing high...
Read More
New Let’s Talk About Cost TV ad asks: Why aren’t patients sharing in savings at the pharmacy counter?
By Priscilla VanderVeer | July 9, 2019
For the last two years, our Let’s Talk About Cost campaign has sought to answer questions people have about their medicine costs and advance a dialogue on how we can make medicines more affordable...
Read More
Study finds hospitals continue to mark up medicines up to 500% of their cost
By Holly Campbell | July 9, 2019
A new analysis from the Moran Company found hospitals continue to charge, on average, five times their cost for medicines, driving up cost sharing and premiums for patients across the country....
Read More
Three reasons why the latest Rx Savings Solutions analysis is misleading
By Holly Campbell | July 2, 2019
Yesterday, multiple news outlets featured data from Rx Savings Solutions on medicine price trends. These data reflect list price increases, ignoring the significant rebates and discounts on...
Read More
Medicare Monday (100)
340B Spotlight (43)
Cost & Consequence (0)
